Affimed Shares Outstanding 2014-2024 | AFMDQ
Affimed shares outstanding from 2014 to 2024. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Affimed Annual Shares Outstanding
(Millions of Shares) |
| 2023 |
15 |
| 2022 |
14 |
| 2021 |
12 |
| 2020 |
8 |
| 2019 |
6 |
| 2018 |
6 |
| 2017 |
4 |
| 2016 |
3 |
| 2015 |
3 |
| 2014 |
3 |
| 2013 |
2 |
| 2012 |
2 |
Affimed Quarterly Shares Outstanding
(Millions of Shares) |
| 2024-09-30 |
16 |
| 2024-06-30 |
15 |
| 2024-03-31 |
15 |
| 2023-12-31 |
15 |
| 2023-09-30 |
15 |
| 2023-06-30 |
15 |
| 2023-03-31 |
15 |
| 2022-12-31 |
14 |
| 2022-09-30 |
15 |
| 2022-06-30 |
15 |
| 2022-03-31 |
12 |
| 2021-12-31 |
12 |
| 2021-09-30 |
12 |
| 2021-06-30 |
12 |
| 2021-03-31 |
12 |
| 2020-12-31 |
8 |
| 2020-09-30 |
9 |
| 2020-06-30 |
8 |
| 2020-03-31 |
8 |
| 2019-12-31 |
6 |
| 2019-09-30 |
6 |
| 2019-06-30 |
6 |
| 2019-03-31 |
6 |
| 2018-12-31 |
6 |
| 2018-09-30 |
6 |
| 2018-06-30 |
6 |
| 2018-03-31 |
5 |
| 2017-12-31 |
4 |
| 2017-09-30 |
5 |
| 2017-06-30 |
4 |
| 2017-03-31 |
4 |
| 2016-12-31 |
3 |
| 2016-09-30 |
3 |
| 2016-06-30 |
3 |
| 2016-03-31 |
3 |
| 2015-12-31 |
3 |
| 2015-09-30 |
3 |
| 2015-06-30 |
3 |
| 2015-03-31 |
2 |
| 2014-12-31 |
2 |
| 2014-09-30 |
0 |
| 2014-06-30 |
1 |
| 2014-03-31 |
1 |
| 2013-09-30 |
0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.001B |
$0.009B |
|
Affimed N.V is a clinical stage biopharmaceutical company. It is engaged in developing single and combination therapies to treat cancers. The company's product pipeline consists of AFM13, AFM24, AFM26, AFM11 and AMV564 which are in clinical stage. Affimed N.V, formerly known as Affimed Therapeutics B.V., is based in Heidelberg, Germany.
|
